<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8508183</journal-id>
<journal-id journal-id-type="pubmed-jr-id">1289</journal-id>
<journal-id journal-id-type="nlm-ta">Pediatr Neurol</journal-id>
<journal-id journal-id-type="iso-abbrev">Pediatr. Neurol.</journal-id>
<journal-title-group>
<journal-title>Pediatric neurology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0887-8994</issn>
<issn pub-type="epub">1873-5150</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30424962</article-id>
<article-id pub-id-type="pmc">6314307</article-id>
<article-id pub-id-type="doi">10.1016/j.pediatrneurol.2018.10.005</article-id>
<article-id pub-id-type="manuscript">NIHMS1512238</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Longitudinal effects of everolimus on white matter diffusion in Tuberous Sclerosis Complex</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Peters</surname>
<given-names>Jurriaan M.</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Prohl</surname>
<given-names>Anna</given-names>
</name>
<degrees>BA</degrees>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kapur</surname>
<given-names>Kush</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nath</surname>
<given-names>Audrey</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Scherrer</surname>
<given-names>Benoit</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Clancy</surname>
<given-names>Sean</given-names>
</name>
<degrees>BA</degrees>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Prabhu</surname>
<given-names>Sanjay P.</given-names>
</name>
<degrees>MBBS</degrees>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sahin</surname>
<given-names>Mustafa</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Franz</surname>
<given-names>David Neal</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Warfield</surname>
<given-names>Simon K.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Krueger</surname>
<given-names>Darcy A</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Division of Epilepsy and Clinical Neurophysiology, Boston, MA 02115</aff>
<aff id="A2"><label>2</label>Translational Neuroscience Center, Department of Neurology, Boston Children’s Hospital and Harvard Medical School, Boston, MA 02115</aff>
<aff id="A3"><label>3</label>Computational Radiology Laboratory, Department of Radiology, Boston Children’s Hospital and Harvard Medical School, Boston, MA 02115</aff>
<aff id="A4"><label>4</label>Department of Neurology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.</aff>
<author-notes>
<corresp id="CR1">Department of Correspondence: Jurriaan M. Peters, MD, PhD. Division of Epilepsy and Clinical Neurophysiology, Boston Children’s Hospital. 300 Longwood Ave – Fegan 9, Boston, MA 02115, USA. Tel +1 617 355 5606 Fax +1 617 730 0463 <email>jurriaan.peters@childrens.harvard.edu</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>12</day>
<month>11</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>18</day>
<month>10</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>1</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>1</month>
<year>2020</year>
</pub-date>
<volume>90</volume>
<fpage>24</fpage>
<lpage>30</lpage>
<!--elocation-id from pubmed: 10.1016/j.pediatrneurol.2018.10.005-->
<abstract id="ABS1">
<sec id="S1">
<title>Objective:</title>
<p id="P1">To study longitudinal effects of everolimus, an inhibitor of the mechanistic target of rapamycin (mTOR), on callosal white matter diffusion tensor imaging (DTI) in patients with tuberous sclerosis complex (TSC).</p>
</sec>
<sec id="S2">
<title>Methods:</title>
<p id="P2">Serial imaging data spanning 9 years was used from the open label, Phase I/II trial (NCT00411619) and open-ended extension phase of everolimus for the treatment of subependymal giant cell astrocytoma (SEGA) associated with TSC. From 28 patients treated with everolimus, and 25 untreated control patients, 481 MRI scans were available. Rigorous quality control resulted in omission of all scans with DWI data in &lt;15 directions or &gt;8 artifacted volumes, and all post-surgical scans. We applied a linear mixed-effects model to the remaining 125 scans (17 treated, 24 controls) for longitudinal analysis of each DTI metric of manually drawn callosal regions of interest.</p>
</sec>
<sec id="S3">
<title>Results:</title>
<p id="P3">On a population level, mTOR inhibition was associated with a decrease in mean diffusivity. In addition, in treated patients only, a decrease of radial diffusivity was observed; in untreated patients only, an increase of axial diffusivity was seen. In patients below age 10, effect-sizes were consistently greater, and longer treatment was associated with greater rate of diffusion change. There was no correlation between DTI metrics and reduction of SEGA volume, or everolimus serum levels.</p>
</sec>
<sec id="S4">
<title>Conclusion:</title>
<p id="P4">Effects from mTOR overactivity on white matter microstructural integrity in TSC were modified through pharmacological inhibition of mTOR. These changes sustained over time, were greater with longer treatment and in younger patients during a time of rapid white matter maturation.</p>
</sec>
</abstract>
<kwd-group>
<kwd>children</kwd>
<kwd>tuberous sclerosis complex</kwd>
<kwd>diffusion tensor imaging</kwd>
<kwd>mechanistic target of rapamycin</kwd>
<kwd>mTOR</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>